[ad_1]
(HealthDay) -The use of the primary human papillomavirus (HPV) test versus cytology results in a reduced likelihood of cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3 +) at 48 months, according to a study published in July 3 issue of Journal of the American Medical Association .
Gina Suzanne Ogilvie, MD, of the University of British Columbia in Vancouver, Canada, and her colleagues conducted a randomized trial to evaluate the cumulatively confirmed cumulative incidence of CIN3 + detected up to 1 year. at 48 months inclusive by the HPV test alone or liquid cytology. Overall, 19,009 women were randomized to the intervention and control groups (9,552 and 9,457 respectively). The women in the intervention group received the HPV test, while those in the control group received liquid cytology tests.
Overall, 8,296 and 8,078 in the intervention and control groups completed the study. The researchers found that far fewer CIN3 + and CIN2 + were detected in the intervention group compared to the control group at 48 months. For every 1,000 women, the incidence rates were 2.3 and 5.5 for CIN3 + in the intervention and control groups, respectively; "In women undergoing screening for cervical cancer, the use of primary HPV compared to cytologic testing resulted in a significantly lower probability of CIN3 + at 48 months. ", write the authors." Further research is needed to understand long-term clinical outcomes as well as cost-effectiveness. "
Several authors have revealed financial links with the pharmaceutical industry.
Learn more:
Low incidence of cervical cancer, CIN3 + in HIV-negative women
More information:
Summary / Full text
Editorial (registration or payment may be required)
Source link
